Azitra Announces Proposed Public Offering of Common Stock

Core Viewpoint - Azitra, Inc. has initiated a public offering of its common stock to raise funds for working capital and general corporate purposes [1][2]. Group 1: Company Overview - Azitra, Inc. is a clinical-stage biopharmaceutical company focused on precision dermatology [5]. - The company's lead product, ATR-12, targets Netherton syndrome, a rare skin disease with no approved treatments [5]. - ATR-12 is currently in a Phase 1b clinical trial for adult patients with Netherton syndrome [5]. - Azitra's second product, ATR-04, is being developed for EGFR inhibitor-associated rash and has received Fast Track designation from the FDA [5]. - Approximately 150,000 people in the U.S. are affected by EGFRi associated rash [5]. - Azitra utilizes a proprietary platform of engineered proteins and a microbial library of around 1,500 bacterial strains, enhanced by AI and machine learning technologies [5]. Group 2: Offering Details - The public offering is conducted under an effective shelf registration statement filed with the SEC [3]. - Maxim Group LLC is the sole placement agent for the offering [2]. - The offering is subject to market conditions, and there is no guarantee regarding its completion or terms [1].